[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
July 2015

Risks of Different Testosterone PreparationsToo Much, Too Little, Just Right

Author Affiliations
  • 1Department of Medicine, University of Colorado School of Medicine, Aurora
  • 2Research Service, Denver Veterans Affairs Medical Center, Denver, Colorado
JAMA Intern Med. 2015;175(7):1197-1198. doi:10.1001/jamainternmed.2015.1580

There is a developing story that the increased use of testosterone therapy without a diagnosis of hypogonadism is associated with an elevated cardiovascular risk for some patients. In this issue of JAMA Internal Medicine, Layton and coauthors1 deepen our knowledge with their analysis of 3 large databases (Truven MarketScan and Medicare cohorts from the United States and the Clinical Practice Research Datalink cohort from the United Kingdom) to ask whether they could detect a difference in cardiovascular or cerebrovascular events and mortality in patients newly prescribed testosterone therapy in the form of injectable testosterone compared with testosterone gels or patches.

First Page Preview View Large
First page PDF preview
First page PDF preview